Statin pleiotropism and atherosclerotic plaque rupture

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 353-354

  Jackson, Christopher L ^a   Johnson, Jason L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Apolipoprotein E knockout mouse; Plaque rupture; Pleiotropism; Statin

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; FLUINDOSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; INFLAMMATION; LETTER; NEUTROPHIL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; THROMBUS; UNSTABLE ANGINA PECTORIS;

EID: 70349432274     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.050     Document Type: Letter

References (21)

1. Nakamura K, Sasaki T, Cheng XW, Iguchi A, Sato K, Kuzuya M. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009, doi:10.1016/j.atherosclerosis.2009.02.014, in press.
2. Johnson J., Carson K., Williams H., Karanam S., Newby A., Angelini G., et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 111 (2005) 1422-1430
3. Jackson C.L., Bennett M.R., Biessen E.A., Johnson J.L., and Krams R. Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27 (2007) 714-720
4. Bevilacqua M., Bettica P., Milani M., Vago T., Rogolino A., Righini V., et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 79 (1997) 84-87
5. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., and Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135 (2002) 284-292
6. Undas A., Celinska-Lowenhoff M., Lowenhoff T., and Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4 (2006) 1029-1036
7. Liu L., Zhao S.P., Zhou H.N., Li Q.Z., and Li J.X. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 50 (2007) 50-55
8. Orem C., Uydu H.A., Yilmaz R., Gokce M., Baykan M., Eminagaoglu S., et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J 45 (2004) 977-987
9. Dangas G., Smith D.A., Unger A.H., Shao J.H., Meraj P., Fier C., et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 83 (2000) 688-692
10. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102 (2008) 209-217
11. Leclercq A., Houard X., Philippe M., Ollivier V., Sebbag U., Meilhac O., et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 82 (2007) 1420-1429
12. Naruko T., Ueda M., Haze K., van der Wal A.C., van der loos C.M., Itoh A., et al. Neutrophil infiltratin of culprit lesions in acute coronary syndromes. Circ Res 106 (2002) 2894-2900
13. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31 (2000) 40-47
14. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., and Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
15. Krams R., Verheye S., van Damme L.C., Tempel D., Mousavi Gourabi B., Boersma E., et al. In vivo temperature heterogeneity is associated with plaque regions of increased MMP-9 activity. Eur Heart J 26 (2005) 2200-2205
16. Fukuda D., Shimada K., Tanaka A., Kusuyama T., Yamashita H., Ehara S., et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 97 (2006) 175-180
17. Brown D.L., Desai K.K., Vakili B.A., Nouneh C., Lee H.M., and Golub L.M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24 (2004) 733-738
18. Johnson J.L., George S.J., Newby A.C., and Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102 (2005) 15575-15580
19. Johnson J.L., Fritsche-Danielson R., Behrendt M., Westin-Eriksson A., Wennbo H., Herslof M., et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 71 (2006) 586-595
20. Burke A.P., Kolodgie F.D., Farb A., Weber D.K., Malcom G.T., Smialek J., et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
21. Williams H., Johnson J.L., Carson K.G., and Jackson C.L. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 22 (2002) 788-792